This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
Read the original research
Tirzepatide, a dual GIP/GLP-1 receptor agonist, alleviates metabolic dysfunction-associated steatotic liver disease by reducing the expression of CD36 and OBP2A.
Genes & diseases, 12(6), 101761
Citation
Li, Yun; Sun, Wencong; Liu, Hong; Ruan, Xiong Z. (2025). Tirzepatide, a dual GIP/GLP-1 receptor agonist, alleviates metabolic dysfunction-associated steatotic liver disease by reducing the expression of CD36 and OBP2A.. Genes & diseases, 12(6), 101761. https://doi.org/10.1016/j.gendis.2025.101761